US 7,485,310 B2
	Use of CXCL6 chemokine in the prevention or repair of cartilage defects
Frank Luyten, Kraainem (Belgium); Cosimo De Bari, Aberdeen (United Kingdom); and Francesco Dell'Accio, Bromley (United Kingdom)
Assigned to Tigenix N.V., Leuven (Belgium)
Appl. No. 10/595,072 PCT Filed Aug. 12, 2004, PCT No. PCT/BE2004/000117 § 371(c)(1), (2), (4) Date May 09, 2006, PCT Pub. No. WO2005/014026, PCT Pub. Date Feb. 17, 2005.
Claims priority of provisional application 60/494516, filed on Aug. 12, 2003.
Prior Publication US 2006/0246031 A1, Nov. 02, 2006
Int. Cl. A61K 38/17 (2006.01); C07K 14/435 (2006.01)

U.S. Cl. 424—198.1  [424/184.1; 530/350; 530/399]

8 Claims

1. A method for treatment of a cartilage or osteochondral defect comprising the step of administering an effective amount of Chemokine, CXC Motif, Ligand 6 (CXCL6) to an individual in need thereof, so as to obtain promotion of hyaline cartilage in said cartilage defect or in said osteochondral defect.